Literature DB >> 9923561

Halofuginone inhibits neointimal formation of cultured rat aorta in a concentration-dependent fashion in vitro.

K Liu1, S Sekine, Y Goto, K Iijima, I Yamagishi, K Kondon, M Matsukawa, T Abe.   

Abstract

Halofuginone, an anticoccidial quinoazolinone, can specifically inhibit collagen type alpha1 (I) synthesis and gene expression, and also inhibits cultured smooth muscle cell proliferation. The aim of this study was to investigate the effect of halofuginone on neointimal formation of rat aorta after culture in a concentration-dependent manner in vitro. Thoracic aorta of Wistar rats was removed and manipulated to damage the endothelium under sterile conditions, and culture for 15 days in halofuginone-free or halofuginone-added culture medium (n = 20). Segments of cultured aorta were studied by histologic and immunohistochemical methods. Proliferation of neointimal layers consisting of loose multilayer cellular structure was observed in the halofuginone-free control group after 15 days of rat aorta culture, and neointimal formation was significantly decreased as an increasing concentration of halofuginone was added. As with precultured fresh aorta, no intimal proliferation was observed in the cultured segments of aorta with 500 ng/ml halofuginone added to culture medium. The proliferation of cell nuclear antigen index was significantly higher in the halofuginone-free control group than that in the halofuginone-added groups. The present results suggest that halofuginone can inhibit neointimal formation of rat aorta after culture in a concentration-dependent fashion in vitro.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9923561     DOI: 10.1007/BF02750639

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   1.814


  24 in total

1.  From laminin to lamin: regulation of tissue-specific gene expression by the ECM.

Authors:  N Boudreau; C Myers; M J Bissell
Journal:  Trends Cell Biol       Date:  1995-01       Impact factor: 20.808

2.  Intimal proliferation in an organ culture of human saphenous vein.

Authors:  A A Soyombo; G D Angelini; A J Bryan; B Jasani; A C Newby
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

Review 3.  The future of saphenous vein as a coronary artery bypass conduit.

Authors:  G D Angelini; A C Newby
Journal:  Eur Heart J       Date:  1989-03       Impact factor: 29.983

Review 4.  A review of the histologic changes in vein-to-artery grafts, with particular reference to intimal hyperplasia.

Authors:  R J Dilley; J K McGeachie; F J Prendergast
Journal:  Arch Surg       Date:  1988-06

5.  Porcine aortic organ culture: a model to study the cellular response to vascular injury.

Authors:  A I Gotlieb; P Boden
Journal:  In Vitro       Date:  1984-07

6.  Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells.

Authors:  R N Salomon; C C Hughes; F J Schoen; D D Payne; J S Pober; P Libby
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

7.  Vimentin-containing smooth muscle cells in aortic intimal thickening after endothelial injury.

Authors:  G Gabbiani; E Rungger-Brändle; C de Chastonay; W W Franke
Journal:  Lab Invest       Date:  1982-09       Impact factor: 5.662

8.  Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial.

Authors:  D P Faxon; T E Spiro; S Minor; G Coté; J Douglas; R Gottlieb; R Califf; K Dorosti; E Topol; J B Gordon
Journal:  Circulation       Date:  1994-08       Impact factor: 29.690

9.  Halofuginone, a specific collagen type I inhibitor, reduces anastomotic intimal hyperplasia.

Authors:  E T Choi; A D Callow; N L Sehgal; D M Brown; U S Ryan
Journal:  Arch Surg       Date:  1995-03

10.  Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT).

Authors:  P W Serruys; W Rutsch; G R Heyndrickx; N Danchin; E G Mast; W Wijns; B J Rensing; J Vos; J Stibbe
Journal:  Circulation       Date:  1991-10       Impact factor: 29.690

View more
  4 in total

1.  Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.

Authors:  Merav Leiba; Jana Jakubikova; Steffen Klippel; Constantine S Mitsiades; Teru Hideshima; Yu-Tzu Tai; Adi Leiba; Mark Pines; Paul G Richardson; Arnon Nagler; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2012-04-26       Impact factor: 6.998

2.  Antimalarial activities and therapeutic properties of febrifugine analogs.

Authors:  Suping Jiang; Qiang Zeng; Montip Gettayacamin; Anchalee Tungtaeng; Srisombat Wannaying; Apassorn Lim; Pranee Hansukjariya; Christopher O Okunji; Shuren Zhu; Daohe Fang
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma.

Authors:  Henry B Koon; Barbara Fingleton; Jeannette Y Lee; Julia T Geyer; Ethel Cesarman; Robert A Parise; Merrill J Egorin; Bruce J Dezube; David Aboulafia; Susan E Krown
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

4.  Halofuginone, a specific inhibitor of collagen type 1 synthesis, ameliorates oxidant colonic damage in rats with experimental colitis.

Authors:  Berna Karakoyun; Meral Yüksel; Feriha Ercan; Emine Salva; Işil Işik; Berrak C Yeğen
Journal:  Dig Dis Sci       Date:  2009-04-24       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.